Bisphosphonate-related Osteonecrosis of the Jaws: An Update on Clinical, Pathological and Management Aspects

被引：17

作者：

Ficarra G. ^{[1
,2
,3
]}

Beninati F. ^{[1
]}

机构：

[1] Reference Center for the Study of Oral Diseases, University of Florence, Florence 50134

[2] Azienda Ospedaliero-Universitaria Careggi, Florence

[3] Department of Odonto-Stomatology, University of Florence, Florence 50134

来源：

Head and Neck Pathology | 2007年 / 1卷 / 2期

关键词：

Bisphosphonate; Bone metastasis; Cancer; Jaws; Osteomyelitis; Osteonecrosis; Osteoporosis; Pamidronate; Review; Zoledronic acid;

D O I：

10.1007/s12105-007-0033-2

中图分类号：

学科分类号：

摘要：

Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is mainly observed in patients with multiple myeloma and bone metastasis from solid tumors receiving iv bisphosphonate therapy. The reported incidence of BRONJ is significantly higher with the iv preparations zoledronic acid and pamidronate while the risk appears to be minimal for patients receiving oral bisphosphonates. Currently available published incidence data for BRONJ are based on retrospective studies and estimates of cumulative incidence range from 0.8 to 12%. The mandible is more commonly affected than the maxilla (2:1 ratio), and 60-70% of cases are preceded by a dental surgical procedure. The signs and symptoms that may occur before the appearance of clinical evident osteonecrosis include changes in the health of periodontal tissues, non-healing mucosal ulcers, loose teeth and unexplained soft-tissue infection. Although the definitive role of bisphosphonates remains to be elucidated, the inhibition of physiologic bone remodeling and angiogenesis by these potent drugs impairs the regenerative capacity of the bone causing the development of BRONJ. Tooth extraction as a precipitating event is a common observation. The significant benefits that bisphosphonates offer to patients clearly surpass the risk of potential side effects; however, any patient for whom prolonged bisphosphonate therapy is indicated, should be provided with preventive dental care in order to minimize the risk of developing this severe condition. This article provides an update review of current knowledge about clinical, pathological and management aspects of BRONJ. © Humana Press Inc. 2007.

引用

页码：132 / 140

页数：8

共 64 条

[1]

Wu S., Dahut W.L., Gulley J.L., The use of bisphosphonates in cancer patients, Acta Oncol, 46, pp. 581-591, (2007)

[2]

Wang J., Goodger N.M., Pogrel M.A., Osteonecrosis of the jaws associated with cancer chemotherapy, J Oral Maxillofac Surg, 61, pp. 1104-1107, (2003)

[3]

Rosenberg T.J., Ruggiero S., Osteonecrosis of the jaws associated with the use of bisphosphonates, J Oral Maxillofac Surg, 61, (2003)

[4]

Marx R.E., Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic, J Oral Maxillofac Surg, 61, pp. 1115-1117, (2003)

[5]

Migliorati C.A., Bisphosphonates and oral cavity avascular bone necrosis, New Engl J Med, 21, pp. 4253-4254, (2003)

[6]

Ruggiero S.L., Mehrotra B., Rosenberg T.J., Et al., Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases, J Oral Maxillofac Surg, 62, pp. 527-534, (2004)

[7]

Lugassy G., Shaham R., Nemets A., Et al., Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: A new clinical entity, Am J Med, 117, pp. 440-441, (2004)

[8]

Bagan J.V., Murillo J., Poveda R., Et al., Avascular jaw osteonecrosis in association with cancer chemotherapy: Series of 10 cases, J Oral Pathol Med, 34, pp. 120-123, (2005)

[9]

Vannucchi A.M., Ficarra G., Antonioli E., Et al., Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma, Br J Haematol, 128, (2005)

[10]

Ficarra G., Beninati F., Rubino I., Et al., Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment, J Clin Periodontol, 32, pp. 1123-1128, (2005)

← 1 2 3 4 5 6 7 →